Tetraphase Pharmaceuticals

www.tphase.com

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

GINKGO BIOWORKS ANNOUNCES PARTNERSHIP WITH TOTIENT TO IDENTIFY NEUTRALIZING ANTIBODIES AGAINST COVID-19

Ginkgo Bioworks | September 11, 2020

news image

Today, Ginkgo Bioworks announced a partnership with Totient, an AI-driven drug discovery company emerging from stealth, to rapidly identify neutralizing antibodies against COVID-19. Through this partnership, Totient will leverage Ginkgo's bioengineering platform to express and screen thousands of antibody candidates with the aim of identifying broadly neutralizing therapeutic antibodies against COVID-19 for further development. Totient leverages tertiary lymphoid structures (TLSs) to identif...

Read More

Industrial Impact

ORDAŌS AND NONEXOMICS ANNOUNCE RESEARCH COLLABORATION

Ordaōs and NonExomics | September 29, 2022

news image

Ordaōs, a biotechnology company designing novel miniPROTM mini-proteins to help drug hunters deliver life-saving treatments, and NonExomics, a company specializing in the identification of novel targets from non-conventional protein-coding regions, announced a proof-of-concept research collaboration. As part of this endeavor, Ordaōs will use its proprietary design engine to generate and rank novel miniPRO™ candidates that meet specific target product profiles, beginning with three targets....

Read More

Medical

MINDMED ANNOUNCES THE START OF THE FIRST EVER CLINICAL TRIAL MEASURING AND EVALUATING MDMA AND LSD

MindMed | January 21, 2021

news image

MindMed, a main psychedelic medication biotech organization, reported today the beginning of the principal ever clinical preliminary estimating and assessing MDMA and LSD utilized in mix in the human body. The preliminary will be directed at the University Hospital Basel Liechti Lab, in Basel, Switzerland. If administered in combination with LSD, MDMA may expand positive abstract medication impacts, including positive state of mood and empathy, and lessen the negative feelings and...

Read More

MedTech

ORACLE AND OXFORD NANOPORE TEAM UP TO IMPROVE HEALTHCARE AND SPEED DISCOVERY OF NEW MEDICAL BREAKTHROUGHS

Oracle | September 16, 2021

news image

Advances in DNA/RNA sequencing promise to revolutionize how medical communities identify, detect, and treat diseases and manage public health threats. To make this technology more accessible and increase its impact, Oracle has teamed up with Oxford Nanopore Technologies, the company behind a new generation of high-performance, rapid, scalable, and accessible sequencing technology. Oracle and Oxford Nanopore have recently begun a collaboration to jointly explore several potential n...

Read More
news image

GINKGO BIOWORKS ANNOUNCES PARTNERSHIP WITH TOTIENT TO IDENTIFY NEUTRALIZING ANTIBODIES AGAINST COVID-19

Ginkgo Bioworks | September 11, 2020

Today, Ginkgo Bioworks announced a partnership with Totient, an AI-driven drug discovery company emerging from stealth, to rapidly identify neutralizing antibodies against COVID-19. Through this partnership, Totient will leverage Ginkgo's bioengineering platform to express and screen thousands of antibody candidates with the aim of identifying broadly neutralizing therapeutic antibodies against COVID-19 for further development. Totient leverages tertiary lymphoid structures (TLSs) to identif...

Read More
news image

Industrial Impact

ORDAŌS AND NONEXOMICS ANNOUNCE RESEARCH COLLABORATION

Ordaōs and NonExomics | September 29, 2022

Ordaōs, a biotechnology company designing novel miniPROTM mini-proteins to help drug hunters deliver life-saving treatments, and NonExomics, a company specializing in the identification of novel targets from non-conventional protein-coding regions, announced a proof-of-concept research collaboration. As part of this endeavor, Ordaōs will use its proprietary design engine to generate and rank novel miniPRO™ candidates that meet specific target product profiles, beginning with three targets....

Read More
news image

Medical

MINDMED ANNOUNCES THE START OF THE FIRST EVER CLINICAL TRIAL MEASURING AND EVALUATING MDMA AND LSD

MindMed | January 21, 2021

MindMed, a main psychedelic medication biotech organization, reported today the beginning of the principal ever clinical preliminary estimating and assessing MDMA and LSD utilized in mix in the human body. The preliminary will be directed at the University Hospital Basel Liechti Lab, in Basel, Switzerland. If administered in combination with LSD, MDMA may expand positive abstract medication impacts, including positive state of mood and empathy, and lessen the negative feelings and...

Read More
news image

MedTech

ORACLE AND OXFORD NANOPORE TEAM UP TO IMPROVE HEALTHCARE AND SPEED DISCOVERY OF NEW MEDICAL BREAKTHROUGHS

Oracle | September 16, 2021

Advances in DNA/RNA sequencing promise to revolutionize how medical communities identify, detect, and treat diseases and manage public health threats. To make this technology more accessible and increase its impact, Oracle has teamed up with Oxford Nanopore Technologies, the company behind a new generation of high-performance, rapid, scalable, and accessible sequencing technology. Oracle and Oxford Nanopore have recently begun a collaboration to jointly explore several potential n...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us